Medicinal product name Amitriptylinum Meda 25 mg coated tablets
Pharmaceutical form Coated tablet
Strength 25 mg 
Information from the MAH on shortages Not available
predicted availability date: not notified
Legal status Rx Prescription (Pr.)
KZSR Reimbursed medicines reference product
Package leaflet MS Word document 10-09-2020
Summary of product characteristics MS Word document 10-09-2020
ATC code N06AA09 Psychoanaleptics

Important notice

Additional information regarding the use for persons aged 75+

If used as "PSYCHOANALEPTICS"
SubstanceClassComment
Amitriptylini hydrochloridumDAvoid use in older persons. Anticholinergic. Sedative. Serotonergic. Risk of QT prolongation. Low doses (10-20mg) can be used for treating neuropathic pain. Significant adverse effects include confusion, cognitive disorder, tremor, arrhytmia, tachycardia, orthostatic hypotension and serotonin syndrome. Increases risk for falls. Take several interactions into account. Weakens the efficacy of anti-Alzheimer´s drugs.

Medicinal products (1)

Availability of medicinal product Wholesalers Package size, content Primary packaging Maximum admissible pharmacy price (€ incl. VAT) Product No. Labelling
 Not available (according to the information provided by wholesalers)
predicted availability date: not notified
currently no information on availability from any wholesaler N60
(25 mg)
PVC/Al blister 1.96 
KZSR*
96-0515-01 Labelling text Labelling text Jul 26, 2018
* Indication about medicine on the List of state reimbursed medicines is just informative. Source of the information is the National Health Service. For details please visit the NHS website.

Registration information

Marketing authorisation No. 96-0515
Date of authorisation Nov 14, 1996
MA valid until For unlimited time
Marketing authorisation holder, country Meda Pharma, SIA, Latvia